A Phase III Comparison of CHOP Versus m-BACOD Versus ProMACE-CytaBOM Versus MACOP-B in Patients with Intermediate or High-Grade Non-Hodgkin's Lymphoma
Publication Information Expand/Collapse
PMid: PMID29370458 | PMC number: PMC5963502
Survival by Hispanic Ethnicity Among Cancer Patients participating in SWOG Clinical Trials
PMid: PMID27986655 | PMC number: PMC5370550
PMid: PMID24633940 | PMC number: PMC4137041
Association between BMI at treatment initiation and cancer survival across multiple SWOG trials
Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. PMC2724852; PMID: 19584328
Natural history of central nervous system (CNS) relapse in patients with aggressive non-hodgkin's lymphoma: a 20 year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group [PMID19047289]
Minority report: how best to analyze clinical trial data to address disparities
The Southwest Oncology Group: progress in cancer research [PMID18929152]
Central nervous system (CNS) relapse in agressive non-Hodgkin's lymphoma; does CNS prophylaxis work?
The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic and clinical features
Burkitt-like lymphoma: a distinctive morphology and phenotype with poor prognosis
BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: An Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study.
Treatment of grey zone lymphomas
Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma.
Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas.
A Southwest Oncology Group (SWOG) analysis of the anaplastic large cell lymphoma (ALCL) entities in the revised European American lymphoma (REAL) classification.
Prognostic significance of the Ki-67 associated proliferative antigen in aggressive non-Hodgkin's lymphoma: A prospective Southwest Oncology Group (SWOG) trial.
African americans treated on SWOG NHL studies: Similar incidence, received dose intensity and outcome to caucasian patients.
Factors affecting reduced survival of the elderly with intermediate and high grade lymphoma: An analysis of SWOG-8516 (INT 0067) - the national high priority lymphoma study - a randomized comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B.
A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: Results of SWOG-8516 (Intergroup 0067), the national high-priority lymphoma study
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
A phase III comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B in patients with intermediate or high-grade non-Hodgkin's lymphoma: Preliminary results of SWOG-8516 (Intergroup 0067).
Southwest Oncology Group clinical trials for intermediate andhigh-grade non-hodgkin's lymphomas.